Association Health Plans
Executive Summary
The Blue Cross/Blue Shield Association is lobbying against association health plans as its top legislative priority in 2003. In a story on BCBSA's approach to the generic drug debate this year, "The Pink Sheet" incorrectly stated the association's position on the health plan issue (1"The Pink Sheet" May 19, 2003, p. 30)...
You may also be interested in...
Blue Cross/Blue Shield Testing Generic Drug Ad Themes For 2003
The Blue Cross/Blue Shield Association is developing an ad campaign with the message that expanded use of generic drugs will free up resources to spend on future medical innovations
Executives On The Move: Changes At The Top At Enzolytics, Dyne Therapeutics And Seres Therapeutics
Recent moves in the industry include new chief financial officers at LENZ Therapeutics and Botanix Pharmaceuticals, plus new chief medical officers at Vigil Neuroscience and Voyager Therapeutics.
Israel's Gamida Cell Survives By Selling To Lender
Having finally secured US approval for Omisirge, Gamida was hoping to bag a strategic partner for the cell therapy. A year on, no suitable partner has been identified and the firm is delisting from the NASDAQ and going private.